Champions Oncology (CSBR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Sep 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CSBR SEC filings page.
Champions Oncology, Inc. (CSBR) reported $60.7M in revenue over the twelve months to Jul 31, 2026, up 6.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue grew, but rising costs and slower collections turned FY2025 profitability into FY2026 cash consumption.
FY2026 revenue rose4.4% while gross profit slipped0.1% , revealing that growth was not producing additional gross dollars. That squeeze met a faster-expanding expense base, turning the prior year's operating profit into a FY2026 operating loss of$1.1M .
Operating cash flow reversed from
Total liabilities fell
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Champions Oncology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Champions Oncology, Inc. held $4.9M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $4.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Champions Oncology, Inc. scores 38/100 among other emerging companies.
Champions Oncology, Inc. had 14M shares outstanding at the end of fiscal year 2026, against 14M in fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Champions Oncology, Inc. scores 69/100 among other emerging companies.
Champions Oncology, Inc. spent $9.1M on research and development in fiscal year 2026, which was 15.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Champions Oncology, Inc. scores 46/100 among other emerging companies.
Champions Oncology, Inc. reported revenue of $59.4M in fiscal year 2026, against $56.9M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Champions Oncology, Inc. scores 54/100 among other emerging companies.
Champions Oncology, Inc.'s operations used $4.5M of cash in fiscal year 2026, against $7.4M generated in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Champions Oncology, Inc. scores 62/100 among other emerging companies.
Champions Oncology, Inc.'s cash, cash equivalents and investments came to $4.9M at the end of fiscal year 2026, against $22.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Champions Oncology, Inc. scores 28/100 among other emerging companies.
Champions Oncology, Inc. scores -0.41, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $81.1M against total assets of $27.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Champions Oncology, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Champions Oncology, Inc. reported a net loss of $1.2M while operations used $4.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Champions Oncology, Inc. generated $15.2M in revenue in Q1 2027. This represents an increase of 8.8% from the same quarter a year earlier. Against the prior quarter it is up 10.1%.
Champions Oncology, Inc.'s EBITDA was -$95K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Champions Oncology, Inc. reported a net loss of $426K in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q1 2027.
Cash & Balance Sheet
Champions Oncology, Inc. recorded an outflow of $547K in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents a decrease of 198.7% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Champions Oncology, Inc. held $4.4M in cash as of Q1 2027; no long-term debt figure is on record for that period.
Not reported for Q1 2027.
Margins & Returns
Champions Oncology, Inc.'s gross margin was 50.5% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is up 7.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.
Champions Oncology, Inc.'s operating margin was -2.7% in Q1 2027, reflecting core business profitability. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Champions Oncology, Inc.'s net profit margin was -2.8% in Q1 2027, showing the share of revenue converted to profit. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.
Champions Oncology, Inc.'s quarterly ROE was -10.9% in Q1 2027: one quarter's net income over shareholder equity, not annualized. This is up 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.8 percentage points.
Capital Allocation
Champions Oncology, Inc. invested $2.3M in research and development in Q1 2027. This represents an increase of 12.6% from the same quarter a year earlier. Against the prior quarter it is up 10.8%.
Champions Oncology, Inc. invested $55K in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 19.6% from the same quarter a year earlier. Against the prior quarter it is down 77.0%.
Not reported for Q1 2027.
CSBR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M+8.8% | $13.8M+12.0% | $16.6M-2.8% | $15.0M+11.5% | $14.0M-0.5% | $12.4M-11.8% | $17.0M+41.8% | $13.5M+16.6% |
| Cost of Revenue | $7.5M-5.8% | $6.8M-6.4% | $8.8M+33.5% | $7.3M-2.2% | $8.0M+13.1% | $7.3M+0.3% | $6.6M-15.7% | $7.4M+12.2% |
| Gross Profit | $7.7M+28.3% | $7.0M+38.2% | $7.7M-25.9% | $7.8M+28.2% | $6.0M-14.2% | $5.1M-24.7% | $10.4M+149.9% | $6.1M+22.3% |
| R&D Expenses | $2.3M+12.6% | $2.1M+7.7% | $2.3M+32.1% | $2.6M+54.9% | $2.1M+43.2% | $2.0M-4.2% | $1.7M-21.4% | $1.7M-32.8% |
| SG&A Expenses | $5.8M+30.2% | $5.4M+12.4% | $5.6M+34.2% | $5.0M+36.6% | $4.4M+5.2% | $4.8M+6.5% | $4.2M-7.8% | $3.6M-17.2% |
| Operating Income | -$409Kn/m | -$522Kn/m | -$276K-106.1% | $185K-74.7% | -$527K-139.7% | -$2.0Mn/m | $4.5Mn/m | $732Kn/m |
| EBITDA | -$95Kn/m | -$178Kn/m | $65K-98.7% | $542K-52.1% | -$169K-109.5% | -$1.7M-858.3% | $4.9Mn/m | $1.1Mn/m |
| Income Tax | $11K-21.4% | $172Kn/m | $42K+82.6% | $18K+63.6% | $14K-33.3% | -$130Kn/m | $23K+109.1% | $11K0.0% |
| Net Income | -$426Kn/m | -$698Kn/m | -$279K-106.2% | $268K-63.2% | -$466K-135.5% | -$1.8Mn/m | $4.5Mn/m | $728Kn/m |
| EPS (Basic) | -$0.03n/m | -$0.04n/m | -$0.02-106.1% | $0.02-60.0% | -$0.03-130.0% | -$0.14n/m | $0.33n/m | $0.05n/m |
| EPS (Diluted) | N/A | -$0.04n/m | -$0.02-106.5% | $0.02-60.0% | -$0.03-133.3% | -$0.13n/m | $0.31n/m | $0.05n/m |
| Diluted Shares (Avg) | N/A | N/A | 14M-3.3% | 14M+3.1% | 14M-1.8% | N/A | 14M+5.7% | 14M+3.9% |
Not reported in any period shown, so not listed: Interest Expense.
CSBR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $33.3M+9.0% | $27.0M-16.6% | $28.4M-7.1% | $30.2M+19.5% | $30.5M+22.5% | $32.3M+23.8% | $30.6M+14.3% | $25.2M-10.8% |
| Current Assets | $19.3M-8.2% | $19.2M-14.0% | $20.2M+2.5% | $21.3M+51.5% | $21.0M+59.5% | $22.4M+63.9% | $19.7M+49.2% | $14.1M+0.5% |
| Cash & Equivalents | $4.4M-57.8% | $4.9M-50.2% | $7.1M+122.6% | $8.5M+209.2% | $10.3M+257.0% | $9.8M+273.8% | $3.2M-28.3% | $2.8M-50.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | $13.6M+43.6% | $13.2M+17.6% | $12.1M-23.5% | $11.5M+10.2% | $9.5M+4.9% | $11.2M+17.6% | $15.8M+99.9% | $10.5M+36.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% |
| Total Liabilities | $28.8M+6.7% | $22.9M-19.8% | $24.1M-4.3% | $25.9M+5.6% | $27.0M+6.9% | $28.6M+1.9% | $25.2M-12.8% | $24.6M-12.9% |
| Current Liabilities | $18.7M-17.5% | $19.9M-16.5% | $20.7M+4.1% | $22.1M+17.4% | $22.7M+18.4% | $23.9M+10.7% | $19.9M-9.6% | $18.9M-10.0% |
| Non-Current Liabilities | $10.1M+134.4% | $3.0M-36.4% | $3.4M-35.9% | $3.8M-33.5% | $4.3M-29.4% | $4.7M-27.3% | $5.3M-23.1% | $5.7M-21.4% |
| Total Equity | $3.9M+11.0% | $3.9M+4.4% | $4.3M-21.7% | $4.2M+512.3% | $3.5Mn/m | $3.8Mn/m | $5.5Mn/m | $681K+632.3% |
| Retained Earnings | -$81.5Mn/m | -$81.1Mn/m | -$80.4Mn/m | -$80.1Mn/m | -$80.4Mn/m | -$79.9Mn/m | -$78.1Mn/m | -$82.6Mn/m |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
CSBR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$492K-182.0% | -$2.0M-129.1% | -$1.3M-373.3% | -$1.7Mn/m | $600K+92.9% | $6.9Mn/m | $490Kn/m | -$283K-148.0% |
| Depreciation & Amortization | $314K-12.3% | $300K-25.0% | $341K-14.3% | $357K-10.5% | $358K-20.3% | $400K-20.0% | $398K-17.3% | $399K-17.6% |
| Stock-Based Compensation | $766K+268.3% | N/A | $423K+65.2% | $249K+2666.7% | $208K-19.4% | N/A | $256K-32.5% | $9K-83.0% |
| Capital Expenditures | $55K+19.6% | $239K-5.5% | $37K-11.9% | $242K+157.4% | $46Kn/m | $253K+8333.3% | $42K-54.3% | $94K+19.0% |
| Free Cash Flow | -$547K-198.7% | -$2.2M-133.8% | -$1.4M-407.1% | -$2.0Mn/m | $554K+78.1% | $6.6Mn/m | $448Kn/m | -$377K-173.9% |
| Investing Cash Flow | -$55Kn/m | -$238Kn/m | -$14Kn/m | -$242Kn/m | -$46Kn/m | -$253K-8533.3% | -$42Kn/m | -$94Kn/m |
| Financing Cash Flow | $33Kn/m | -$19Kn/m | -$36Kn/m | $168K-29.7% | -$14Kn/m | -$32Kn/m | $0n/m | $239K+78.4% |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | $0n/m | $0n/m | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid.
CSBR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.5%+7.7pp | 50.8%+9.7pp | 46.7%-14.5pp | 51.7%+6.8pp | 42.9%-6.8pp | 41.1%-7.1pp | 61.2%+26.5pp | 44.9%+2.1pp |
| Operating Margin | -2.7%+1.1pp | -3.8%+12.5pp | -1.7%-28.1pp | 1.2%-4.2pp | -3.8%-13.2pp | -16.2%-14.3pp | 26.4%+47.8pp | 5.4%+22.3pp |
| Net Margin | -2.8%+0.5pp | -5.0%+9.8pp | -1.7%-28.1pp | 1.8%-3.6pp | -3.3%-12.7pp | -14.8%-14.1pp | 26.4%+47.4pp | 5.4%+23.3pp |
| Return on Equity | -10.9%+2.3pp | -17.7%+30.9pp | -6.5%-88.7pp | 6.4%-100.5pp | -13.3% | -48.6% | 82.2% | 106.9%+2333.8pp |
| Return on Assets | -1.3%+0.2pp | -2.6%+3.1pp | -1.0%-15.7pp | 0.9%-2.0pp | -1.5%-6.8pp | -5.7%-5.3pp | 14.7%+24.1pp | 2.9%+10.2pp |
| Current Ratio | 1.03+0.1x | 0.960.0x | 0.980.0x | 0.96+0.2x | 0.93+0.2x | 0.94+0.3x | 0.99+0.4x | 0.75+0.1x |
| Liabilities-to-Equity | 7.41-0.3x | 5.82-1.8x | 5.62+1.0x | 6.22-29.8x | 7.70 | 7.57 | 4.60 | 36.06-267.2x |
| Asset Turnover | 0.460.0x | 0.51+0.1x | 0.580.0x | 0.500.0x | 0.46-0.1x | 0.38-0.2x | 0.56+0.1x | 0.53+0.1x |
| FCF Margin | -3.6%-7.6pp | -16.2%-69.7pp | -8.3%-10.9pp | -13.2%-10.4pp | 4.0%+1.8pp | 53.5%+66.5pp | 2.6%+11.0pp | -2.8%-7.2pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Note: The current ratio is below 1.0 (0.96), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Champions Oncology, Inc. CSBR | FY2026 | $59.4M | -$1.2M | -2.0% | $67.2M | 50/100 |
| Atara Biotherapeutics, Inc ATRA | FY2025 | $120.8M | $32.7M | 27.1% | $83.3M | 42/100 |
| Ovid Therapeutics Inc. OVID | FY2025 | $7.3M | -$17.4M | N/A | $441.4M | 66/100 |
| MacroGenics, Inc. MGNX | FY2025 | $149.5M | -$74.6M | -49.9% | $155.4M | 57/100 |
| Surrozen, Inc. SRZN | FY2025 | $3.5M | -$242.0M | N/A | $347.1M | 43/100 |
Where Champions Oncology, Inc. Ranks
Frequently Asked Questions
What is Champions Oncology, Inc.'s annual revenue?
Champions Oncology, Inc. (CSBR) reported $59.4M in total revenue for fiscal year 2026. This represents a 4.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Champions Oncology, Inc.'s revenue growing?
Champions Oncology, Inc. (CSBR) revenue grew by 4.4% year-over-year, from $56.9M to $59.4M in fiscal year 2026.
Is Champions Oncology, Inc. profitable?
No, Champions Oncology, Inc. (CSBR) reported a net loss of $1.1M over the trailing 12 months to July 31, 2026. In fiscal year 2026 it reported a net loss of $1.2M, with a net profit margin of -2.0%.
What is Champions Oncology, Inc.'s EBITDA?
Champions Oncology, Inc. (CSBR) had EBITDA of $260K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Champions Oncology, Inc.'s gross margin?
Champions Oncology, Inc. (CSBR) had a gross margin of 48.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Champions Oncology, Inc.'s operating margin?
Champions Oncology, Inc. (CSBR) had an operating margin of -1.9% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Champions Oncology, Inc.'s net profit margin?
Champions Oncology, Inc. (CSBR) had a net profit margin of -2.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Champions Oncology, Inc.'s return on equity (ROE)?
Champions Oncology, Inc. (CSBR) has a return on equity of -29.8% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Champions Oncology, Inc.'s free cash flow?
Champions Oncology, Inc. (CSBR) recorded an outflow of $5.0M in free cash flow during fiscal year 2026. This represents a -172.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Champions Oncology, Inc.'s operating cash flow?
Champions Oncology, Inc. (CSBR) recorded an outflow of $4.5M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Champions Oncology, Inc.'s total assets?
Champions Oncology, Inc. (CSBR) had $27.0M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Champions Oncology, Inc.'s capital expenditures?
Champions Oncology, Inc. (CSBR) invested $564K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Champions Oncology, Inc. spend on research and development?
Champions Oncology, Inc. (CSBR) invested $9.1M in research and development during fiscal year 2026.
What is Champions Oncology, Inc.'s current ratio?
Champions Oncology, Inc. (CSBR) had a current ratio of 0.96 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
What is Champions Oncology, Inc.'s liabilities-to-equity ratio?
Champions Oncology, Inc. (CSBR) had a liabilities-to-equity ratio of 5.82 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
What is Champions Oncology, Inc.'s return on assets (ROA)?
Champions Oncology, Inc. (CSBR) had a return on assets of -4.3% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Champions Oncology, Inc.'s P/E ratio?
Champions Oncology, Inc. (CSBR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to July 31, 2026). The market capitalization is $67.2M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Champions Oncology, Inc.'s price-to-sales ratio?
Champions Oncology, Inc. (CSBR) trades at 1.1x sales, its market capitalization divided by $60.7M revenue, trailing 12 months to July 31, 2026. The market capitalization is $67.2M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Champions Oncology, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Champions Oncology, Inc. (CSBR) held $4.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.5M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Champions Oncology, Inc.'s Altman Z-Score?
Champions Oncology, Inc. (CSBR) has an Altman Z-Score of -0.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Champions Oncology, Inc.'s Piotroski F-Score?
Champions Oncology, Inc. (CSBR) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Champions Oncology, Inc.'s earnings high quality?
Champions Oncology, Inc. (CSBR) reported a net loss of $1.2M while operations used $4.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Champions Oncology, Inc.?
Champions Oncology, Inc. (CSBR) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.